Obesity Facts · 2012 · 28 citations · 25 references
MedicineEndocrinologyGynecologyHormone BiochemistryMetabolic RegulationReproductive EndocrinologyAdipose TissueInsulin ResistanceMetabolic EndocrinologyPolycystic Ovary SyndromeWeight LossWeight ManagementEnergy-restricted DietsInsulin Resistance AssessmentObesity-associated Insulin ResistancePolycystic Ovary Syndrome ComorbidityPolycystic Ovary Syndrome TreatmentPolycystic Ovary Syndrome-associated Insulin ResistanceWaist Circumference MeasurementWeight Loss Drug
OBJECTIVE: To assess the effects of weight loss on serum adipokine levels in polycystic ovary syndrome (PCOS). METHODS: We determined serum leptin, adiponectin, resistin, and visfatin levels in 60 overweight/obese women with PCOS and 48 BMI-matched female volunteers. Measurements were repeated after 24 weeks of treatment with orlistat 120 mg 3 times per day along with an energy-restricted diet. RESULTS: At baseline, serum visfatin concentration was higher in patients with PCOS than in controls (p = 0.036); serum levels of leptin, adiponectin, and resistin did not differ between the two groups. After 24 weeks, a significant reduction in BMI and waist circumference was observed in both patients with PCOS and controls (p < 0.001 vs. baseline in both groups). Also serum leptin levels decreased in both patients with PCOS and controls (p < 0.001 vs. baseline in both groups). The reduction in serum leptin levels did not differ between groups. Serum adiponectin, resistin, and visfatin levels did not change in either group. CONCLUSIONS: Leptin, adiponectin, and resistin do not appear to play major pathogenetic roles in overweight/obese patients with PCOS. In contrast, visfatin emerges as a potentially important mediator of the endocrine abnormalities of these patients. However, serum visfatin levels are not substantially affected by weight loss.
25
Men at risk: occupation and male infertility
Paul Claman · Fertility and Sterility · 2004 · 2.4K citations
Medicine, Urology, Infertility +8